Self-assembled ferric-shikonin-quercetin (FSQ) nanoparticles co-delivering R848 enable lactate reduction, ICD induction, and immune modulation in vitro.
To overcome inadequate tumor immunogenicity and the immunosuppressive tumor microenvironment, a self-assembled nanomedicine (R848@FSQ) is developed by coordinating the chemotherapeutic drugs shikonin (SHK) and quercetin (Qu) with Fe3 + to form a metal-phenolic network (MPN), and is simultaneously loaded with the immune...